Invega FDA Approval History
FDA Approved: Yes (First approved December 19, 2006)
Brand name: Invega
Generic name: paliperidone
Company: Janssen, L.P.
Treatment for: Schizophrenia, Schizoaffective Disorder
Invega (paliperidone) is a once-daily oral atypical antipsychotic indicated for the acute and maintenance treatment of schizophrenia, and the acute treatment of schizoaffective disorder.
Invega Sustenna is an extended-release injectable formulation of paliperidone administered once-monthly for the treatment of schizophrenia and schizoaffective disorder.
Development timeline for Invega
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.